Synergistic effect of 15-lipoxygenase 2 and radiation in killing head-and-neck cancer

Cancer Gene Therapy

Volumn 15, Issue 5, 2008, Pages 323-330

  Yang, Q ^a   Feng, Y ^a   Schultz, C J ^a   Li, X A ^a   Wu, H ^a   Wang, D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

15 lipoxygenase 2; 15S HETE; Egr 1 promotor; Head and neck cancer; Radiotherapy

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONIC ACID; CASPASE 3; COMPLEMENTARY DNA; EARLY GROWTH RESPONSE FACTOR 1; HYDROXYICOSATETRAENOIC ACID; LIPOCORTIN 5; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN 15 LIPOXYGENASE 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CELL KILLING; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE INSERTION; GENETIC TRANSFECTION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RADIATION DOSE; UPREGULATION;

APOPTOSIS; ARACHIDONATE 15-LIPOXYGENASE; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; GENES, REPORTER; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS; LIPOXYGENASE; LUCIFERASES; PROMOTER REGIONS (GENETICS); RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 41949103643     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.9     Document Type: Article

References (35)

1. Chao KS. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer. Semin Radiat Oncol 2002; 12(Suppl 1): 20-25.
2. Eisbruch A. Clinical aspects of IMRT for head-and-neck cancer. Med Dosim 2002; 27: 99-104.
3. Mezhir JJ, Smith KD, Posner MC, Senzer N, Yamini B, Kufe DW et al. Ionizing radiation: genetic switch for cancer therapy. Cancer Gene Ther 2006; 13: 1-6.
4. Keyse SM. The induction of gene expression in mammalian cells by radiation. Semin Cancer Biol 1993; 4: 119-128.
5. Weichselbaum RR, Hallahan DE, Beckett MA, Mauceri HJ, Lee H, Sukhatme VP et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res 1994; 54: 4266-4269.
6. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1: 786-791.
7. Kim SH, Kim JH, Kolozsvary A, Brown SL, Freytag SO. Preferential radiosensitization of 9L glioma cells transduced with HSV-tk gene by acyclovir. J Neurooncol 1997; 33: 189-194.
8. Meyer RG, Kupper JH, Kandolf R, Rodemann HP. Early growth response-1 gene (Egr-1) promoter induction by ionizing radiation in U87 malignant glioma cells in vitro. Eur J Biochem 2002; 269: 337-346.
9. Datta R, Rubin E, Sukhatme V, Qureshi S, Hallahan D, Weichselbaum RR et al. Ionizing radiation activates transcription of the EGR-1 gene via CArG elements. Proc Natl Acad Sci 1992; 89: 10149-10153.
10. Hallahan DE, Spriggs DR, Beckett MA, Kufe DW, Weichselbaum RR. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci 1989; 86: 10104-10107.
11. Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 2004; 22: 592-601.
12. Mundt AJ, Vijayakumar S, Nemunaitis J, Sandler A, Schwartz H, Hanna N et al. A phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 2004; 10: 5747-5753.
13. Brash AR, Boeglin WE, Chang MS. Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci 1997; 94: 6148-6152.
14. Attar TE, Lin H. Prostaglandin synthesis by squamous carcinoma cells of head and neck, and its inhibition by nonsteroidal anti-inflammatory drugs. J Oral Pathol 1987; 16: 483-487.
15. Cherukuri DP, Nelson MA. Do elevated levels of eicosanoids play a role in head and neck cancer recurrence and metastasis? Implications for prevention and treatment. Cancer Biol Ther 2004; 3: 853-854.
16. Shappell SB, Boeglin WE, Olson SJ, Kasper S, Brash AR. 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 1999; 155: 235-245.
17. Xu XC, Shappell SB, Liang Z, Song S, Menter D, Subbarayan V et al. Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia 2003; 5: 121-127.
18. Wang D, Chen S, Feng Y, Yang Q, Campbell BH, Tang X et al. Reduced expression of 15-lipoxygenase 2 in human head and neck carcinomas. Tumor Biol 2006; 27: 261-273.
19. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL et al. Inverse relationship between 15-lipoxygenase-2 and PPAR-γ gene expression in normal epithelia compared with tumor epithelia. Neoplasia 2005; 7: 280-293.
20. Jack GS, Brash AR, Olson SJ, Manning S, Coffey CS, Smith JA et al. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 2000; 31: 1146-1154.
21. Tang S, Bhatia B, Maldonado CJ, Yang P, Newman RA, Liu J et al. Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem 2002; 277: 16189-16201.
22. Bhatia B, Tang S, Yang P, Doll A, Aumüeller G, Newman RA et al. Cell-autonomous induction of functional tumor suppressor 15-lipoxygenase 2 (15-LOX-2) contributes to replicative senescence of human prostate progenitor cells. Oncogene 2005; 24: 3583-3595.
23. Chen Y, Sato M, Fujimura S, Endo C, Sakurada A, Aikawa H et al. Expression of Bcl-2, Bax, and p53 proteins in carcinogenesis of squamous cell lung cancer. Anticancer Res 1999; 19: 1351-1356.
24. Dey S, Spring PM, Arnold S, Valentino J, Chendil D, Regine WF et al. Low-dose fractionated radiation potentiates the effects of paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res 2003; 9: 1557-1565.
25. Marples B, Scott SD, Hendry JH, Embleton MJ, Lashford LS, Margison GP. Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther 2000; 7: 511-517.
26. Park JO, Lopez CA, Gupta VK, Brown CK, Mauceri HJ, Darga TE et al. Transcriptional control of viral gene therapy by cisplatin. J Clin Invest 2002; 110: 403-410.
27. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93: 229-240.
28. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C et al. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999; 400: 378-382.
29. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4: 1046-1052.
30. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998; 95: 8806-8811.
31. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 2000; 60: 1129-1138.
32. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C et al. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001; 61: 497-503.
33. Hsi LC, Wilson LC, Eling TE. Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma. J Biol Chem 2002; 227: 40549-40556.
34. Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, Sabichi AL et al. 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. Oncogene 2006; 25: 6015-6025.
35. Flores AM, Li L, Mchugh NG, Aneskievich BJ. Enzyme association with PPARgamma: evidence of a new role for 15-lipoxygenase type 2. Chem Biol Interact 2005; 151: 121-132.